Viritis is a biotech company focused on transforming drug discovery and development.

Today, developing a single antiviral drug takes more than 10 years, costs up to $2 Billion and 90% of the drugs failed to reach the market.

Our team at Viritis has developed a molecular platform that enables the creation of specific antiviral drugs in mere months, rather than years and with significantly reduced costs.Our platform combines a patented molecule with advanced AI algorithms to create targeted therapies that effectively eliminate pathogens without harming the host.

This approach allows us to rapidly address both existing and emerging health threats.

Early tests showed 97.1% cellular protection against the virus.We are currently raising a seed round which will be supported by the Israeli Innovation Authority which approved our grant request.

This funding will enable us to complete preclinical studies and take our product to market this year.